Bausch + Lomb reported third-quarter revenue of $1.375 billion, a 7% increase from the prior year period, driven by growth across its Vision Care, Surgical, and Pharmaceuticals segments. GAAP net income was $32 million compared to a loss of $28 million in the same quarter last year, while adjusted EBITDA rose to $325 million. The company raised its full-year 2026 revenue guidance to $5.45 billion–$5.55 billion and increased adjusted EBITDA excluding acquired IPR&D guidance to $1.09 billion–$1.14 billion. Bausch + Lomb is a leading global eye health company providing contact lenses, surgical devices, and pharmaceutical products.
